Amgen
Update in progressAMGN (NasdaqGS)
- Company RatingAt RiskCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - General
Amgen is a global biopharmaceutical company that discovers, develops, manufactures, and markets human therapeutics. Its portfolio includes Enbrel, Prolia, XGEVA, Repatha, Nplate, Kyprolis, Aranesp, Evenity, Vectibix, Blincyto, Tepezza, Krystexxa, and other medicines. It serves healthcare providers through distributors and collaborates with AstraZeneca, BeONE Medicines, UCB, Kyowa Kirin, and BeiGene. Founded in 1980, based in Thousand Oaks, California.
Company score
- Sentiment
- -1.78
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 1.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -2.44
- Governance
- -4.59
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -1.36
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -1.57
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Robert A. Bradway
- Founded1980
- Employees31,500
- Websitewww.amgen.com
Identifiers
- ISINUS0311621009
- FIGIBBG000BBS2Y0
- LEI62QBXGPJ34PQ72Z12S66
- CUSIP031162100
- CIK0000318154